Trials need to offer a rescue to assist in recruiting -- a patient getting an experimental treatment wants assurance they will have a rescue option if it fails.
From the trial protocol filed on clinicaltrials.gov: "All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression. "
So DCVax-L was the only other option NWBO was offering other than leaving the trial.
Ex, I don't exactly remember the details but in the presentation by Dr Liau (taken down a day later) she briefly spoke about those that did not crossover. I think she said most were too sick and either couldn't or chose not to cross. I do imagine a few were in the 5% that seem to do well on soc (just my opinion) Hope the series of PRs start coming this week
Market Data 
Markets 
AI
